Vest Financial LLC Invests $1.47 Million in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Vest Financial LLC purchased a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC. The fund purchased 17,520 shares of the medical instruments supplier's stock, valued at approximately $1,470,000. Vest Financial LLC owned about 0.08% of LeMaitre Vascular as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of LMAT. Raymond James Financial Inc. purchased a new stake in LeMaitre Vascular in the fourth quarter valued at approximately $14,900,000. Rockefeller Capital Management L.P. acquired a new stake in LeMaitre Vascular during the 4th quarter valued at approximately $7,787,000. Segall Bryant & Hamill LLC purchased a new stake in shares of LeMaitre Vascular in the 4th quarter valued at $5,446,000. Invesco Ltd. increased its stake in shares of LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after acquiring an additional 58,720 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of LeMaitre Vascular by 7,486.5% during the first quarter. GAMMA Investing LLC now owns 53,864 shares of the medical instruments supplier's stock worth $4,519,000 after purchasing an additional 53,154 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 0.6%

Shares of LMAT stock traded down $0.49 during trading hours on Wednesday, hitting $83.15. 86,921 shares of the company's stock were exchanged, compared to its average volume of 168,113. LeMaitre Vascular, Inc. has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The firm has a market cap of $1.88 billion, a P/E ratio of 45.36, a P/E/G ratio of 2.22 and a beta of 0.83. The firm has a 50 day moving average of $83.68 and a two-hundred day moving average of $90.69.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The company had revenue of $59.87 million for the quarter, compared to analyst estimates of $57.61 million. During the same quarter in the prior year, the company posted $0.44 earnings per share. The business's revenue was up 12.0% on a year-over-year basis. On average, equities analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were paid a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.96%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

Insider Buying and Selling at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 76,868 shares of the business's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the transaction, the chief executive officer now owns 1,796,783 shares of the company's stock, valued at approximately $154,146,013.57. The trade was a 4.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last quarter, insiders sold 100,000 shares of company stock worth $8,556,857. Insiders own 9.50% of the company's stock.

Analysts Set New Price Targets

LMAT has been the topic of several recent research reports. Barrington Research lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Wells Fargo & Company started coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target for the company. Finally, Lake Street Capital raised their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Five analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to MarketBeat.com, LeMaitre Vascular presently has an average rating of "Hold" and a consensus target price of $97.83.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.